DelMar Pharmaceuticals Company Profile (NASDAQ:DMPI)

About DelMar Pharmaceuticals (NASDAQ:DMPI)

DelMar Pharmaceuticals logoDelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being evaluated in a Phase II clinical trial for the treatment of refractory GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Its drug discovery research focuses on identifying validated clinical and commercial-stage compounds, and establishing a scientific rationale for development in orphan drug indications. VAL-083 is an alkylating agent, which crosses the blood-brain-barrier (BBB).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NASDAQ:DMPI
  • CUSIP: N/A
  • Web:
Average Prices:
  • 50 Day Moving Avg: $2.77
  • 200 Day Moving Avg: $3.78
  • 52 Week Range: $2.10 - $10.87
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.97
  • P/E Growth: 0.00
  • Return on Assets: -155.84%
  • Current Ratio: 4.68%
  • Quick Ratio: 4.68%
  • Average Volume: 48,498 shs.
  • Beta: 0.92

Frequently Asked Questions for DelMar Pharmaceuticals (NASDAQ:DMPI)

What is DelMar Pharmaceuticals' stock symbol?

DelMar Pharmaceuticals trades on the NASDAQ under the ticker symbol "DMPI."

When did DelMar Pharmaceuticals' stock split? How did DelMar Pharmaceuticals' stock split work?

DelMar Pharmaceuticals's stock reverse split on Friday, May 20th 2016. The 1-4 reverse split was announced on Thursday, May 19th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 19th 2016. An investor that had 100 shares of DelMar Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

How were DelMar Pharmaceuticals' earnings last quarter?

DelMar Pharmaceuticals Inc (NASDAQ:DMPI) announced its earnings results on Thursday, May, 18th. The company reported ($0.18) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.18). View DelMar Pharmaceuticals' Earnings History.

Where is DelMar Pharmaceuticals' stock going? Where will DelMar Pharmaceuticals' stock price be in 2017?

4 equities research analysts have issued 1-year price targets for DelMar Pharmaceuticals' stock. Their predictions range from $11.00 to $16.00. On average, they anticipate DelMar Pharmaceuticals' share price to reach $13.00 in the next year. View Analyst Ratings for DelMar Pharmaceuticals.

Who are some of DelMar Pharmaceuticals' key competitors?

Who owns DelMar Pharmaceuticals stock?

DelMar Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include SABBY MANAGEMENT, LLC (5.71%). Company insiders that own DelMar Pharmaceuticals stock include Dennis M Brown, Jeffrey Bacha and William J Garner. View Institutional Ownership Trends for DelMar Pharmaceuticals.

How do I buy DelMar Pharmaceuticals stock?

Shares of DelMar Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of DelMar Pharmaceuticals stock cost?

One share of DelMar Pharmaceuticals stock can currently be purchased for approximately $2.20.

Analyst Ratings

Consensus Ratings for DelMar Pharmaceuticals (NASDAQ:DMPI) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $13.00 (490.91% upside)

Analysts' Ratings History for DelMar Pharmaceuticals (NASDAQ:DMPI)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/25/2017Maxim GroupSet Price TargetBuy$11.00MediumView Rating Details
1/5/2017AegisInitiated CoverageBuy$16.00N/AView Rating Details
9/12/2016HC WainwrightReiterated RatingBuy$12.00N/AView Rating Details
7/18/2016Rodman & RenshawReiterated RatingBuyN/AView Rating Details
2/18/2016Roth CapitalInitiated CoverageBuyN/AView Rating Details
(Data available from 5/26/2015 forward)


Earnings History for DelMar Pharmaceuticals (NASDAQ:DMPI)
Earnings by Quarter for DelMar Pharmaceuticals (NASDAQ:DMPI)
Earnings History by Quarter for DelMar Pharmaceuticals (NASDAQ:DMPI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/18/2017($0.18)($0.18)ViewN/AView Earnings Details
2/10/201712/31/2016($0.22)($0.13)ViewN/AView Earnings Details
11/10/20169/30/2016($0.15)($0.23)ViewN/AView Earnings Details
5/13/2016($0.05)($0.03)ViewN/AView Earnings Details
2/16/2016Q2 16($0.03)($0.06)ViewN/AView Earnings Details
9/4/2015Q4 2015($0.09)($0.02)ViewN/AView Earnings Details
5/15/2015Q3 2015($0.07)($0.04)ViewN/AView Earnings Details
2/12/2015Q2 2015($0.06)($0.03)ViewN/AView Earnings Details
11/10/2014Q1 2015($0.07)($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for DelMar Pharmaceuticals (NASDAQ:DMPI)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20172($0.27)($0.19)($0.23)
Q3 20172($0.28)($0.16)($0.22)
Q4 20172($0.55)($0.36)($0.46)
(Data provided by Zacks Investment Research)


Dividend History for DelMar Pharmaceuticals (NASDAQ:DMPI)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for DelMar Pharmaceuticals (NASDAQ:DMPI)
Institutional Ownership Percentage: 1.69%
Insider Trades by Quarter for DelMar Pharmaceuticals (NASDAQ:DMPI)
Insider Trades by Quarter for DelMar Pharmaceuticals (NASDAQ:DMPI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/5/2017Jeffrey BachaCEOBuy2,500$2.20$5,500.00View SEC Filing  
2/1/2017Jeffrey BachaCEOBuy4,000$5.00$20,000.00View SEC Filing  
11/25/2015Jeffrey BachaCEOBuy7,500$1.47$11,025.00View SEC Filing  
10/8/2015Jeffrey BachaCEOBuy3,000$0.80$2,400.00View SEC Filing  
9/18/2015Jeffrey BachaCEOBuy4,000$0.83$3,320.00View SEC Filing  
7/22/2015Dennis M BrownMajor ShareholderBuy75,000$0.60$45,000.00View SEC Filing  
7/16/2015Jeffrey BachaCEOBuy50,000$0.60$30,000.00View SEC Filing  
7/16/2015William J GarnerDirectorBuy16,666$0.60$9,999.60View SEC Filing  
1/22/2015Jeffrey BachaCEOBuy7,500$0.66$4,950.00View SEC Filing  
12/9/2014Jeffrey BachaCEOBuy2,500$0.90$2,250.00View SEC Filing  
11/26/2014Jeffrey BachaCEOBuy2,500$0.92$2,300.00View SEC Filing  
11/21/2014John K BellDirectorBuy8,000$0.95$7,600.00View SEC Filing  
9/18/2014Jeffrey BachaCEOBuy4,000$0.98$3,920.00View SEC Filing  
9/15/2014Jeffrey BachaCEOBuy4,985$0.75$3,738.75View SEC Filing  
9/8/2014John K BellDirectorBuy7,000$0.71$4,970.00View SEC Filing  
9/4/2014John K BellDirectorBuy8,000$0.78$6,240.00View SEC Filing  
4/22/2014John K BellDirectorBuy20,000$1.25$25,000.00View SEC Filing  
3/18/2014Dennis M BrownMajor ShareholderBuy10,000$1.30$13,000.00View SEC Filing  
3/18/2014Robert Joseph Toth JrDirectorBuy25,000$1.30$32,500.00View SEC Filing  
3/4/2014Dennis M BrownMajor ShareholderBuy5,000$1.56$7,800.00View SEC Filing  
2/21/2014Jeffrey BachaCEOBuy5,000$1.00$5,000.00View SEC Filing  
2/13/2014Jeffrey BachaCEOBuy5,000$0.80$4,000.00View SEC Filing  
2/11/2014John K BellDirectorBuy9,000$0.83$7,470.00View SEC Filing  
2/5/2014Robert Joseph Toth JrDirectorBuy9,000$0.88$7,920.00View SEC Filing  
1/31/2014Robert Joseph Toth JrDirectorBuy2,000$0.87$1,740.00View SEC Filing  
1/29/2014Robert Joseph Toth JrDirectorBuy7,500$0.91$6,825.00View SEC Filing  
9/20/2013William J GarnerDirectorBuy5,000$1.00$5,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for DelMar Pharmaceuticals (NASDAQ:DMPI)
Latest Headlines for DelMar Pharmaceuticals (NASDAQ:DMPI)
DateHeadline logoDelMar Pharmaceuticals Inc (DMPI) Given a $11.00 Price Target at Maxim Group - May 25 at 7:26 PM logoDelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2017 Financial Results - May 19 at 8:15 AM logoDelMar Pharmaceuticals Inc (DMPI) Announces Earnings Results, Meets Estimates - May 19 at 7:46 AM logoBRIEF-Delmar formalizes collaboration with PRA Health Sciences for phase 3 trial of val-083 - May 12 at 10:20 PM logoDelMar Presents New Mechanism of Action Data for its Lead Agent VAL-083 in Temozolomide-Resistant Glioblastoma Multiforme (GBM) at the World Federation of Neuro-Oncology Societies (WFNOS) - May 8 at 9:25 AM logoDelMar to Present Poster of Clinical Research with VAL-083 in Patients with Chemo-Resistant Glioblastoma ("GBM") at ASCO Annual Meeting - April 27 at 8:59 AM logoDelMar Pharmaceuticals Collaborates with Duke University to Explore VAL-083 as a Front-Line Treatment for Glioblastoma Multiforme - April 25 at 11:49 AM logoDelMar Pharmaceuticals Announces Closing Of $9,000,000 Public Offering Of Common Stock And Warrants - April 21 at 12:15 PM logoMaxim Group Analysts Give DelMar Pharmaceuticals Inc (DMPI) a $11.00 Price Target - April 13 at 8:08 PM logoDelMar Pharmaceuticals Announces Pricing Of $9,000,000 Public Offering Of Common Stock And Warrants - April 13 at 11:39 AM logoDelMar Pharmaceuticals Announces Proposed Public Offering Of Common Stock And Warrants - April 12 at 4:48 PM logoDelmar Pharma (DMPI) Provides VAL-083 Updates from AACR Meeting - - April 7 at 4:46 PM logoDelMar Pharmaceuticals Provides VAL-083 Updates from the Ongoing American Association for Cancer Research (AACR) Annual Meeting - April 7 at 9:27 AM logoDelMar Pharmaceuticals Inc (DMPI) Receives "Buy" Rating from Maxim Group - April 5 at 4:09 PM logoDelmar Pharma (DMPI) Announces Abstract Presentations for AACR - - March 29 at 8:21 PM logoDelMar Pharmaceuticals Announces Abstract Presentations for the American Association for Cancer Research (AACR) Annual Meeting in April 2017 - March 28 at 12:09 PM logoDelMar Pharmaceuticals to Participate in Key Opinion Leader Luncheon on Glioblastoma Multiforme Featuring Dr. James Perry, MD - March 2 at 10:14 AM logoDMPI: Three New Clinical Trials of VAL-083 To be Initiated in 2017 - February 28 at 4:58 PM logoDELMAR PHARMACEUTICALS, INC. Financials - February 16 at 2:46 PM logoDelmar Pharma (DMPI) Doses First Patient in Phase Two Trial of VAL-083 for MGMT-unmethylated Recurrent GBM - February 13 at 5:29 PM logoDelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2017 Financial Results - February 13 at 5:28 PM logoDelMar Pharmaceuticals Announces Dosing of the First Patient in Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM) - February 13 at 5:28 PM logoDelMar Pharmaceuticals, Inc. - "Optimism and Opportunity as we Initiate Clinical Trials for MGMT-unmethylated GBM Patients at MD Anderson" - January 30 at 10:43 AM logoDelmar Pharma (DMPI), MD Anderson Initiate New Phase Two Trial of VAL-083 for MGMT-unmethylated Recurrent GBM - January 26 at 3:58 AM logoDelMar Pharmaceuticals and MD Anderson Initiate New Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM) - January 25 at 5:57 PM logoDelMar Pharmaceuticals Receives Additional Non-Dilutive Funding from the Government of Canada to Support Expanded Research with Lead Product Candidate VAL-083 - January 9 at 4:37 PM logoDelMar Pharmaceuticals, Inc. - "21st Century Cures Act - A Holiday Gift for New Research in the Fight Against Cancer and Other Serious Diseases" - December 20 at 9:50 AM logoDelMar Pharmaceuticals Receives Notice of Allowance from the US Patent and Trademark Office for Key Patent for VAL-083 - December 14 at 5:48 PM logo8:12 am DelMar Pharma receives a Notice of Allowance from the USPTO for patent entitled, 'Improved Analytical Methods for Analyzing and Determining Impurities in Dianhydrogalactitol' - December 14 at 5:48 PM logoACCUREXA, INC. (ACXA) and Other Medical Device Companies Add Value for Patients and Investors - December 13 at 10:27 PM logoDMPI: Three New Clinical Trials with VAL-083 will be Initiated - November 29 at 5:42 PM logoDelMar Pharmaceuticals Delivers an Address and Presents an Overview of Upcoming GBM Trials with VAL-083 at the CNS Anticancer Drug Discovery Development Conference and Society for NeuroOncology Annual Meeting - November 24 at 8:56 AM logoDelMar Pharmaceuticals Announces Successful Completion of End-of-Phase 2 Meeting with FDA on VAL-083 for the Treatment of Refractory Glioblastoma Multiforme - May 25 at 8:00 AM logoDelMar Pharmaceuticals, Inc. - "Reverse Stock Splits & Uplisting" - May 19 at 10:32 AM logoDelMar Pharmaceuticals Announces Reverse Stock Split in Preparation for Proposed Senior Exchange Uplisting - May 19 at 10:16 AM logoDelMar Pharmaceuticals, Inc. - "60 Minutes, Polio Virus for GBM, and the Promise of Chemo-Immunooncology" - May 16 at 10:21 AM logoDelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2016 Financial Results and Corporate Update - May 13 at 8:00 AM logoFDA Grants Orphan Drug Designation For VAL-083 In Ovarian Cancer - April 21 at 8:00 AM logoSeeThruEquity Issues Update on DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) Highlighting Partnership with MD Anderson - April 14 at 9:00 AM logoBooming Orphan Drug Market Provides Investors with Massive Return Prospects - March 30 at 7:00 AM logo8:31 am DelMar Pharma confirms FDA grants second Orphan Designation for VAL-083 in the treatment of medulloblastoma (see March 14 comment) - March 15 at 8:31 AM logoFDA Grants Second Orphan Designation For VAL-083 - March 15 at 8:30 AM logoDelMar Pharmaceuticals, Inc. - "GBM After Rintegra(R)" - March 11 at 8:40 AM logoDELMAR PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events - February 18 at 10:57 AM logoDMPI: Ready to Initiate Registration Phase II/III Trial - February 18 at 10:00 AM logo4 Stocks to Consider for a Biotech Turnaround - February 17 at 11:55 AM logoEARNINGS SUMMARY: Details of DelMar Pharmaceuticals Inc. Q2 Earnings Report - February 16 at 12:17 PM logoDelMar Pharmaceuticals Inc. Bottom Line Rises 327% In Q2 - February 16 at 12:17 PM logoDelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2016 Financial Results and Corporate Update - February 16 at 7:35 AM logoDELMAR PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report - February 12 at 4:25 PM



DelMar Pharmaceuticals (DMPI) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by Staff